NMRA Neumora Therapeutics, Inc.
Company Analysis
Latest News
🔴 Neumora Therapeutics, Inc. is trading 5.45% down
NMRA is trading at $1.48, down 5.45%.
🟢 Neumora Therapeutics is trading 5.3% up today as it recovers from Phase 3 depression drug failure
Neumora Therapeutics is trading 5.3% up today at $1.69, staging a modest recovery after sharp losses tied to the recent failure of its lead clinical...
🔴 Neumora Therapeutics is trading 5.1% down today after RBC Capital lowered its price target
• Neumora Therapeutics is trading at $1.59 (-5.06%) after RBC Capital lowered its price target to $5.00 from $7.00. • This downgrade follows the company's...
🟢 Neumora Therapeutics is trading 8.5% up today as it rebounds from a recent trial-related collapse
Neumora Therapeutics is trading at $1.79, up 8.5% in after-hours trading, rebounding from a sharp drop tied to failed Phase 3 trials and a major workforce...
🔴 NMRA extends move to 5.2% down
NMRA is trading at $1.64, down 5.2% versus the comparison close of $1.73 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 NMRA is trading 5.5% down today as shares drift lower following failed Phase 3 trials
NMRA is trading at $1.64 (5.5% down) as shares continue to drift lower following June’s sharp selloff tied to failed Phase 3 KOASTAL trials and the...
🟢 NMRA is trading 5.03% up today on technical rebound amid biotech volatility
NMRA is trading at $1.77 (5.03% up) as the stock stages a technical recovery following a significant June selloff linked to failed Phase 3 KOASTAL trials and...
🟢 NMRA is trading 5.9% up today with no clear fresh catalyst
NMRA is trading about 5.9% up now at $1.72, bouncing from recent weakness after June’s Phase 3 KOASTAL trial failure and workforce reduction, which triggered a...
🔴 Neumora Therapeutics, Inc. is trading 5.88% down
NMRA is trading at $1.60, down 5.88%.
🟢 NMRA is trading 5% up today as it extends its rebound from a Phase 3 trial failure selloff
NMRA is trading 5% up today at $1.73 as the stock continues to rebound from a recent selloff triggered by a Phase 3 depression trial failure. • Today's price...
🟢 NMRA is trading 6.7% up today as it extends rebound from trial-failure selloff
NMRA is trading at $1.75 (6.7% up) in pre-market, extending a recovery following the sharp selloff triggered by its Phase 3 depression trial failure. • Recent...
🟢 NMRA is trading 5.3% up today on technical rebound after trial-failure selloff
NMRA is trading 5.3% up at $1.59 on a technical rebound following a sharp selloff earlier this month. • The move appears driven by bargain hunting and...
🟢 NMRA is trading 6% up today on technical repricing after recent trial failure selloff
NMRA is trading 6% up today at $1.60 in pre-market, seeing a modest bounce following a significant collapse earlier this month. • The stock's recent decline...
🔴 NMRA makes sharp 10.9% drop
NMRA is trading at $1.44, down 10.9% versus the comparison close of $1.61 during regular trading. This is a price-movement alert; no separate company-specific...
🔴 NMRA is trading 8.2% down today as selling persists after drug failures and restructuring
NMRA is trading 8.2% down at $1.48 as investors continue to sell following the company’s late-stage depression drug failures and restructuring moves. • The...
Neumora's Depression Drug Struck Out Three Times — Can a Gutted Biotech Pivot Its Way Back From the Brink?
Shares of Neumora Therapeutics sank another 10.1% to $1.45 in pre-market trading Tuesday, extending a brutal selloff that has erased roughly 95% of the stock's...
🔴 NMRA is trading 10.1% down today after Phase 3 trial failures and ongoing legal probes
NMRA is trading at $1.45 (10.1% down) in pre-market, extending recent volatility after its lead depression drug navacaprant failed multiple Phase 3 KOASTAL...
🔴 Neumora Therapeutics, Inc. is trading 9.9% down today, extending recent volatility after last week’s extreme swings
Neumora Therapeutics, Inc. is trading 9.9% down at $1.36 in pre-market, extending its recent volatility after last week’s extreme swings. • The decline...
🔴 Neumora Therapeutics, Inc. is trading 5.2% down today following Phase 3 trial failures and workforce reductions
Neumora Therapeutics, Inc. is trading 5.2% down at $1.45, extending a sharp sell-off triggered by the failure of its lead depression drug candidate. • The...